The share price seems to largely reflect the EPS growth, indicating that investor sentiment towards the shares hasn't changed significantly. The company's consistent positive reception from the market suggests it may be worth watching for potential investment.
IDEXX Laboratories' high P/E ratio, inferior earnings outlook, and slower market growth could lead to a share price decline. This high P/E ratio may not be sustainable, posing a risk to shareholders and potential investors.
愛德士股票討論區
IDEXX Laboratories Stock In The Last 15 Years!
2023Q1營收增長7.6%,營業利潤增長12.9%,淨利潤增長10.4%。
目前市盈率68,市盈率TTM略降到65.8,和增速比估值過高,缺乏投資價值。
暫無評論